Clinical trials: Epileptic
Partial Epilepsy
Cenobamate Expanded Access Program (EAP)
This Cenobamate Expanded Access Program (EAP) is designed to continue providing treatment with Cenobamate (YKP3089) to patients with partial-onset epilepsy that were enrolled in the SK Life Science clinical trial YKP3089C013…
- Trial name
- NCT04513860
- Testing
- YKP3089
- Sponsor
- SK Life Science, Inc.
Small Cell Lung Cancer
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
- Trial name
- NCT03898791
- Testing
- LY3295668 Erbumine
- Where
- 40 sites in United States, Belgium and 6 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Seizures, Epileptic
An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy
The purpose of this observational study is to evaluate the safety of topiramate in adults and children with epilepsy (or seizures) who have not received or have not responded to treatment with previous antiepileptic medication.
- Trial name
- NCT00297323
- Testing
- Topiramate
- Volunteers
- 80 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Seizures
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
- Trial name
- NCT04686786
- Testing
- CVL-865
- Where
- 56 sites in United States, Australia and 5 more
- Volunteers
- 105 people
- Sponsor
- AbbVie
Advanced Solid Tumors
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety of TAS-119 and determine the most appropriate dose in combination with Paclitaxel for subsequent studies in patients with advanced solid tumors.
- Trial name
- NCT02134067
- Testing
- TAS-119, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Taiho Oncology, Inc.
Tuberous Sclerosis Complex
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy.
- Trial name
- NCT05323734
- Testing
- Ganaxolone
- Where
- 63 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy
Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy
Keppra injection is approved in the US as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
- Trial name
- NCT00505934
- Testing
- Levetiracetam
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 19 people
- Sponsor
- UCB Pharma SA
Epilepsy
RNS® System Epilepsy Post-Approval Study
The purpose of the study is to follow patients with partial onset seizures prospectively over 5 years in the real-world environment to gather data on the long-term safety and effectiveness of the RNS System at qualified CECs by…
- Trial name
- PAS (NCT02403843)
- Testing
- RNS System
- Where
- 35 sites in United States
- Volunteers
- 345 people
- Sponsor
- NeuroPace
Epilepsy
Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures
Double-blind, randomized, placebo-controlled, multi-center clinical trial conducted to evaluate levetiracetam as adjunctive therapy in children (4-16 years) with refractory partial onset seizures.
- Trial name
- NCT00615615
- Testing
- Levetiracetam
- Volunteers
- 216 people
- Sponsor
- UCB Pharma
Epilepsy, Complex Partial
Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy
The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.
- Trial name
- NCT00056576
- Testing
- Zonisamide
- Where
- 35 sites in United States, Estonia and 3 more
- Volunteers
- 165 people
- Sponsor
- Eisai Inc.
Epilepsies, Partial
Open-label Extension to Protocol 1042-0600
To allow open-label extension to patients who have completed Protocol 1042-0600.
- Trial name
- NCT00512317
- Testing
- ganaxolone
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy, Epilepsy, Partial
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures. LAMICTAL extended-release is an investigational drug.
- Trial name
- NCT00113165
- Testing
- LAMICTAL extended-release
- Where
- 148 sites in United States, Argentina and 8 more
- Volunteers
- 244 people
- Sponsor
- GlaxoSmithKline
Epilepsy
To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects
Primary objective of this trial was to investigate the pharmacokinetics of single dose and repeated dose applications of lacosamide in healthy male Korean subjects.
- Trial name
- NCT01450111
- Testing
- Lacosamide
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Epilepsy, Seizures
Assessment of the Emfit Mattress Sensor for Detection and Alarm of Night-time Generalized Tonic-clonic Seizures.
Sudden unexpected death in epilepsy (SUDEP) is the most important epilepsy-related mode of death. The exact mechanism of SUDEP is not known. It is thought that cardiac and respiratory factors are involved.
- Trial name
- NCT02661919
- Testing
- Emfit mattress sensor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Emfit, Corp.
Epilepsy
Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9 males and 9 females). The study consisted of three consecutive single-dose treatment periods separated by a washout period of 7 days or…
- Trial name
- NCT02279667
- Testing
- BIA 2-093
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
SCAR
An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate
The reason for this study is to understand if people with certain genes are predisposed to develop severe skin reactions after they are administered Eslicarbazepine Acetate.
- Trial name
- NCT02520557
- Testing
- Blood or Saliva
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sumitomo Pharma America, Inc.
Refractory Epilepsy
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
This is a Phase 2 double-blind, randomized, placebo-controlled study to assess the safety and efficacy of ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC) in subjects with focal…
- Trial name
- NCT04153175
- Testing
- ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)
- Where
- 11 sites in Australia, Israel
- Volunteers
- 30 people
- Sponsor
- Cerebral Therapeutics LLC
Epilepsy
A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
Study is conducted to evaluate the long-term safety and tolerability of lacosamide (LCM) in patients receiving LCM in SP0994 [NCT01465997].
- Trial name
- NCT02582866
- Testing
- Lacosamide
- Where
- 46 sites in Bulgaria, Finland and 13 more
- Volunteers
- 106 people
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy, Seizures
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
The objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, folloiwng a single 600 mg dose…
- Trial name
- NCT00616863
- Testing
- Oxcarbazepine
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Epilepsy With Partial-onset Seizures
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
The purpose of this trial is to assess the efficacy, safety and tolerability of lacosamide administered as add-on therapy with 1 to 3 anti-seizure medications.
- Trial name
- NCT02477839
- Testing
- Lacosamide
- Where
- 88 sites in United States, Argentina and 24 more
- Volunteers
- 255 people
- Sponsor
- UCB BIOSCIENCES, Inc.